BeiGene Ltd has a consensus price target of $283.07, established from looking at the 40 latest analyst ratings. The last 3 analyst ratings were released from Bernstein, JP Morgan, and Guggenheim on March 27, 2024, March 19, 2024, and February 27, 2024. With an average price target of $230.67 between Bernstein, JP Morgan, and Guggenheim, there's an implied 47.49% upside for BeiGene Ltd from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/27/2024 | BGNE | Buy Now | BeiGene | $156.39 | 2.95% | Bernstein | Rebecca Liang | $196 → $161 | Maintains | Market Perform | Get Alert |
03/19/2024 | BGNE | Buy Now | BeiGene | $156.39 | 18.93% | JP Morgan | Jessica Fye | $184 → $186 | Maintains | Overweight | Get Alert |
02/27/2024 | BGNE | Buy Now | BeiGene | $156.39 | 120.6% | Guggenheim | Michael Schmidt | $350 → $345 | Maintains | Buy | Get Alert |
02/06/2024 | BGNE | Buy Now | BeiGene | $156.39 | 18.29% | JP Morgan | Jessica Fye | → $185 | Assumes | → Overweight | Get Alert |
10/26/2023 | BGNE | Buy Now | BeiGene | $156.39 | 82.24% | Citigroup | Yigal Nochomovitz | $290 → $285 | Maintains | Buy | Get Alert |
09/21/2023 | BGNE | Buy Now | BeiGene | $156.39 | 85.43% | Citigroup | Yigal Nochomovitz | $285 → $290 | Maintains | Buy | Get Alert |
09/20/2023 | BGNE | Buy Now | BeiGene | $156.39 | 35.56% | B of A Securities | David Li | $224.13 → $212 | Maintains | Neutral | Get Alert |
09/12/2023 | BGNE | Buy Now | BeiGene | $156.39 | 65.61% | Macquarie | Jake Lynch | → $259 | Initiates | → Outperform | Get Alert |
09/12/2023 | BGNE | Buy Now | BeiGene | $156.39 | 65.61% | RBC Capital | Jake Lynch | → $259 | Initiates | → Outperform | Get Alert |
08/29/2023 | BGNE | Buy Now | BeiGene | $156.39 | 103.98% | Morgan Stanley | Matthew Harrison | $321 → $319 | Maintains | Overweight | Get Alert |
08/17/2023 | BGNE | Buy Now | BeiGene | $156.39 | 83.52% | Jefferies | Kelly Shi | → $287 | Initiates | → Buy | Get Alert |
08/07/2023 | BGNE | Buy Now | BeiGene | $156.39 | 91.83% | JP Morgan | Xiling Chen | $297 → $300 | Maintains | Overweight | Get Alert |
07/17/2023 | BGNE | Buy Now | BeiGene | $156.39 | 75.84% | Citigroup | Yigal Nochomovitz | → $275 | Initiates | → Buy | Get Alert |
06/30/2023 | BGNE | Buy Now | BeiGene | $156.39 | 25.33% | Bernstein | Rebecca Liang | $335 → $196 | Downgrade | Outperform → Market Perform | Get Alert |
04/12/2023 | BGNE | Buy Now | BeiGene | $156.39 | 68.36% | B of A Securities | David Li | $230.1 → $263.3 | Maintains | Neutral | Get Alert |
02/28/2023 | BGNE | Buy Now | BeiGene | $156.39 | 123.8% | Guggenheim | Michael Schmidt | → $350 | Reiterates | → Buy | Get Alert |
02/28/2023 | BGNE | Buy Now | BeiGene | $156.39 | 67.53% | Cowen & Co. | Yaron Weber | $213 → $262 | Maintains | Outperform | Get Alert |
02/28/2023 | BGNE | Buy Now | BeiGene | $156.39 | 105.26% | Morgan Stanley | Matthew Harrison | $325 → $321 | Maintains | Overweight | Get Alert |
01/24/2023 | BGNE | Buy Now | BeiGene | $156.39 | 107.81% | Morgan Stanley | Matthew Harrison | $295 → $325 | Maintains | Overweight | Get Alert |
The latest price target for BeiGene (NASDAQ: BGNE) was reported by Bernstein on March 27, 2024. The analyst firm set a price target for $161.00 expecting BGNE to rise to within 12 months (a possible 2.95% upside). 15 analyst firms have reported ratings in the last year.
The latest analyst rating for BeiGene (NASDAQ: BGNE) was provided by Bernstein, and BeiGene maintained their market perform rating.
The last upgrade for BeiGene Ltd happened on October 13, 2022 when Guggenheim raised their price target to $205. Guggenheim previously had a neutral for BeiGene Ltd.
The last downgrade for BeiGene Ltd happened on June 30, 2023 when Bernstein changed their price target from $335 to $196 for BeiGene Ltd.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.
While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a maintained with a price target of $196.00 to $161.00. The current price BeiGene (BGNE) is trading at is $156.39, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.